Novo Nordisk patent lapse opens door for Canadian Ozempic generics

Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Battle over inhaler shape ends badly for Boehringer

21 May 2026 European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.

Americas

Jones Day adds in-house biologics specialist to Boston office

20 May 2026 The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.

Americas

Kirkland & Ellis subject of alleged conflict in trade secrets clash

19 May 2026 In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".

More features

Battle over inhaler shape ends badly for Boehringer

Chinese medtech company fined by UPC over injunction breaches

Healthcare leads sweeping AI partnership in Singapore

Jones Day adds in-house biologics specialist to Boston office

Kirkland & Ellis subject of alleged conflict in trade secrets clash

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme

Orrick lands five-member M&A team in Paris

AbbVie’s trade secret suit against a Chinese rival gets green light

Novo Nordisk patent lapse opens door for Canadian Ozempic generics

More on this story

Editor's picks

Editor's picks

More features